Form 8-K - Current report:
SEC Accession No. 0001193125-26-234862
Filing Date
2026-05-21
Accepted
2026-05-21 17:07:30
Documents
13
Period of Report
2026-05-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d128795d8k.htm   iXBRL 8-K 30398
2 EX-1.1 d128795dex11.htm EX-1.1 195001
3 EX-5.1 d128795dex51.htm EX-5.1 6464
  Complete submission text file 0001193125-26-234862.txt   401515

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA rlay-20260520.xsd EX-101.SCH 3166
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rlay-20260520_lab.xml EX-101.LAB 17234
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rlay-20260520_pre.xml EX-101.PRE 10803
16 EXTRACTED XBRL INSTANCE DOCUMENT d128795d8k_htm.xml XML 3503
Mailing Address 60 HAMPSHIRE STREET CAMBRIDGE MA 02139
Business Address 60 HAMPSHIRE STREET CAMBRIDGE MA 02139 617-370-8837
Relay Therapeutics, Inc. (Filer) CIK: 0001812364 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39385 | Film No.: 261009780
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)